J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore ...

GlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

GlaxoSmithKline Pharmaceuticals Q1 net profit rises 12% to Rs 279 crore, despite slight dip in total income. Company highlights upcoming oncology drug launches.

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to ...